Work

Oesophageal cancer with liver metastasis that showed a complete response to low-dose nedaplatin and 5-FU combined with radiation therapy: A case report

Year: 2018

Type: article

Abstract: Palliative anticancer drug therapy is often performed for unresectable, advanced-stage oesophageal cancer.Patients with poor general condition may not be able to undergo high-dose cisplatin plus fluorouracil (5-FU) therapy due to a high-risk of adverse events.Herein, we report a patient with advanced oesophageal carcinoma and poor general condition, accompanied by severe liver injury due to metastasis, who received palliative chemoradiotherapy.The administration of high-dose cisplatin was not found to be beneficial, and the treatment regimen was switched to low-dose nedaplatin and 5-FU therapy.Subsequently, there was a significant reduction in the liver metastasis that resulted in an improvement of the hepatic function; this allowed the patient to receive outpatient anticancer treatment.Even after the patient became resistant to the primary treatment, changing anticancer drugs allowed treatment to continue, and as a result we were able to prolong the patient's life by approximately 600 days.This therapy with low-dose nedaplatin resulted in an improvement in the general condition and long-term survival of the patient; additionally, the drug has low nephrotoxicity.Hence, it may be considered a significant advancement in the treatment of unresectable, advanced-stage oesophageal cancer.

Source: Clinical Case Reports and Reviews

DOI: 10.15761/jaa.1000111